ADIPOQ and metabolic syndrome: Generally, reduced adiponectin levels have been detected in patients with obesity, type II diabetes, and metabolic syndrome and, hence, adiponectin appears to be an insulin-sensitizing, anti-inflammatory, and anti-apoptotic mediator [4].